跳到正文
← 返回论文列表与筛选
阅读说明

本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。

DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。

引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。

关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。

分类依据与纠错

AI 根据所提供的论文材料归类:摘要的核心方法是连续标记条件下的分位数回归与分位数型效力推断。

反馈分类问题

正在核对关联版本…

代码、数据与补充材料

正在核对对应版本的资源…

关注这篇论文的作者
Lianqiang Qu
Liuquan Sun
Yanqing Sun

连续标记特异的分位数回归模型

研究问题
当竞争风险的失败类型由仅在未删失失败时观测的连续标记表示时,如何开展标记特异的分位数回归和疫苗效力推断?
方法与思路
作者借用标记邻域内的信息,构造诱导平滑估计方程,并研究估计量沿连续标记和分位数范围变化的渐近性质。
材料陈述的贡献
摘要称,论文提出连续标记特异的分位数模型与分位数型疫苗效力指标,发展估计和检验方法,并应用于首次 HIV 疫苗效力试验。
阅读关注点
应核对分位数目标与标记特异效力的定义、删失条件、邻域平滑的带宽选择,以及跨标记和分位数的推断保证。
阅读边界
仅据所给 Crossref 摘要,无法判断删失机制要求、效力指标的因果解释或有限样本误差,也未提供应用的具体结果。

原文摘要

Summary Quantile regression has become a widely used tool for analysing competing risk data. However, quantile regression for competing risk data with a continuous mark is still scarce. The mark variable is an extension of cause of failure in a classical competing risk model where cause of failure is replaced by a continuous mark only observed at uncensored failure times. An example of the continuous mark variable is the genetic distance that measures dissimilarity between the infecting virus and the virus contained in the vaccine construct. In this article, we propose a novel mark-specific quantile regression model. The proposed estimation method borrows strength from data in a neighbourhood of a mark and is based on an induced smoothed estimation equation, which is very different from the existing methods for competing risk data with discrete causes. The asymptotic properties of the resulting estimators are established across mark and quantile continuums. In addition, a mark-specific quantile-type vaccine efficacy is proposed and its statistical inference procedures are developed. Simulation studies are conducted to evaluate the finite sample performances of the proposed estimation and hypothesis testing procedures. An application to the first HIV vaccine efficacy trial is provided.

笔记与分组
相关领域论文